menu
    • menu

    Company profile for Synthekine

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific, selective and potent cytokine therapies. Our targeted protein engineering guided by our deep experience in immunology provides transformative immunotherapies for the treatment of cancer and autoimmune disorders. We are discovering and developing engineered derivatives of therapeutically relevant, naturally occurring cytokine...
    Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific, selective and potent cytokine therapies. Our targeted protein engineering guided by our deep experience in immunology provides transformative immunotherapies for the treatment of cancer and autoimmune disorders. We are discovering and developing engineered derivatives of therapeutically relevant, naturally occurring cytokines. These carefully engineered proteins provide tunable agonism of cytokine signaling while minimizing undesired activities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SynthekineUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1505 O'Brien Drive Menlo Park, California 94025
    Telephone
    Telephone
    650.271.9888
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://synthekine.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/synthekine
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/synthekine

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Synthekine Presents Updated STK-012 Data for NSCLC at AACR 2026
    Synthekine Presents Updated STK-012 Data for NSCLC at AACR 2026

    17 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260317549668/en/Synthekine-Announces-AACR-2026-Oral-Presentation-of-Updated-Phase-1a1b-Clinical-and-Translational-Data-for-STK012-in-FirstLine-Nonsquamous-NSCLC-with-Features-of-Immunotherapy-Resistance

    BUSSINESSWIRE
    17 Mar 2026
    Share Share
    Synthekine, Merck Launch STK-012/Keytruda Trial for NSCLC Cancer
    Synthekine, Merck Launch STK-012/Keytruda Trial for NSCLC Cancer

    26 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260226901519/en/Synthekine-Announces-Clinical-Trial-Collaboration-with-Merck-to-Evaluate-STK-012-In-Combination-with-Keytruda-Pembrolizumab-and-Chemotherapy-in-Ongoing-Randomized-Phase-2-Trial-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    26 Feb 2026
    Share Share
    Synthekine Names John A. Orwin Chair Of Board
    Synthekine Names John A. Orwin Chair Of Board

    23 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-23/synthekine-appoints-biotechnology-and-pharmaceutical-industry-veteran-john-a-orwin-as-chair-of-its

    PHARMIWEB
    23 Feb 2026
    Share Share
    First Patient Dosed in SYNERGY-101 Ph2 Trial of STK-012
    First Patient Dosed in SYNERGY-101 Ph2 Trial of STK-012

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113131381/en/First-Patient-Dosed-in-SYNERGY-101-a-Global-Randomized-Phase-2-Clinical-Trial-of-STK-012-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    Synthekine Reveals Positive Phase 1A/1B Trial Results
    Synthekine Reveals Positive Phase 1A/1B Trial Results

    07 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251107945337/en/Synthekine-Presents-Positive-Initial-Results-from-Phase-1a1b-Clinical-Trial-of-STK-012-Plus-Pembrolizumab-and-Chemotherapy-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    07 Nov 2025
    Share Share
    Synthekine to Present STK-012 Combo Data in NSCLC at SITC 2025
    Synthekine to Present STK-012 Combo Data in NSCLC at SITC 2025

    30 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251030999592/en/Synthekine-Announces-Late-Breaking-Oral-Presentation-of-Initial-Clinical-Data-of-STK-012-Plus-Pembrolizumab-and-Chemotherapy-in-First-Line-PD-L1-Negative-Nonsquamous-NSCLC-at-SITC-2025-Annual-Meeting

    BUSINESSWIRE
    30 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search